[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.237.51.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 654
Citations 0
Comment & Response
August 27, 2019

PD-L1 Status and Survival in Patients With Lung Cancer

Author Affiliations
  • 1Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
  • 2Medical Department, 3D Medicines Inc, Shanghai, China
JAMA. 2019;322(8):783. doi:10.1001/jama.2019.9177

To the Editor As part of a study using clinical data linked to comprehensive genomic profiling results obtained from routine care, Dr Singal and colleagues1 explored programmed death-ligand 1 (PD-L1) status and clinical outcomes among patients with non–small cell lung cancer (NSCLC) who received anti–programmed cell death protein 1 (PD-1)/PD-L1 therapy. They found that PD-L1 status (negative vs positive; 50% staining as cutoff) was not related to overall survival, regardless of treatment line. However, patients receiving different treatment lines should be analyzed separately. The KEYNOTE-042 study2 and KEYNOTE-024 study3 indicated that the overall survival of patients with NSCLC administered pembrolizumab as first-line therapy was dependent on PD-L1 status.

×